Reversible erythromycin ototoxicity.
Loss of auditory acuity and tinnitus may occur, even after oral treatment at standard doses.
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D004917:Erythromycin / Q000009:adverse effects*; D005602:France; D006311:Hearing Disorders / Q000139:chemically induced*; D006801:Humans; D018942:Macrolides / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D018942:Macrolides; D004917:Erythromycin